Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
HOME > REGULATORY
REGULATORY
- Japan to Launch Pilot Project for Adopting Fair Market Value in Clinical Trial Costs
February 28, 2025
- LDP Lawmakers Urge Generic Industry to Ramp Up Production
February 28, 2025
- J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
February 28, 2025
- LDP, Komeito, Ishin Agree to Set Up Consultive Body for Social Security Reform
February 26, 2025
- Coordinate Patent Issues with Originators before Listing: MHLW to Generic Firms
February 26, 2025
- Care Avoidance from Copay Cap Hike Likely to Result in 195 Billion Yen Cost Reduction
February 25, 2025
- PMDA Lists Info Needed for Pediatric Development Plan Confirmation
February 25, 2025
- MHLW to Shorten Procedure for Generic Product Integration to 1.5 Months
February 21, 2025
- Takeda’s Livmarli, BMS’s Camzyos and More Up for MHLW Panel Review on March 6
February 21, 2025
- Japan to Pen Fact Sheet for Sanofi’s High-Dose Flu Jab
February 21, 2025
- Japan Approves CSL’s HAE Med Andembry, Tecentriq Sarcoma Use, and More
February 21, 2025
- Ex-Lawmakers Launch Council for Revamping Japan’s Drug Innovation
February 20, 2025
- Chuikyo OKs Pricing Rules for FY2025 Drug Price Revision
February 20, 2025
- CDP Submits Bill Calling for Outright Freeze on Copay Cap Reform
February 20, 2025
- Sakigake Tag Withdrawn for 2 Boehringer Drugs
February 20, 2025
- Pfizer Pulls Japan NDA for Hemophilia Gene Therapy Beqvez as Program Called Off Globally
February 20, 2025
- Ishiba Vows to Take Steps on OTC-Like Meds from FY2026, Freeze Certain Hikes in Copay Caps
February 19, 2025
- Japan Cabinet OKs 5-Year Healthcare Strategy from FY2025
February 19, 2025
- Minister Touts “Balanced” Off-Year Revision after USCC Letter
February 19, 2025
- Espha’s Januvia Generic on Approval Roster towards June Listing
February 18, 2025
ページ
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…